Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
In Reply We thank Dr Pocinki for sharing his experience with pharmacogenetic testing over the past year. He notes that “with the exception of specific warfarin testing,” pharmacogenetic testing in his patient population has improved clinical decision making and patient outcomes. He cites his experience treating a young woman with chronic pain and “NSAID [nonsteroidal anti-inflammatory drug] intolerance” in whom pharmacogenetic testing showed to be a poor metabolizer of almost all NSAIDs, but suggested she could be treated with naproxen, which is metabolized by a different pathway. Dr Pocinki concludes that “waiting for the results of future, well-designed, adequately powered studies needlessly condemns countless patients to experience avoidable adverse reactions and treatment failures.”
Kazi DS, Hlatky MA. The Value of Pharmacogenetic Testing—Reply. JAMA Intern Med. 2015;175(2):314-315. doi:10.1001/jamainternmed.2014.7023